New drug LAD106 enters first human safety tests
NCT ID NCT07471932
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a new drug called LAD106 in 93 healthy adults aged 18 to 45. The main goal is to see if it is safe and how the body processes it. Participants will receive either LAD106, a similar drug (lebrikizumab), or a placebo. This research is a first step to gather basic safety information before testing in patients with a disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LAD106
- What could go wrong
- This is a very early Phase 1 study in healthy volunteers, so it cannot show whether LAD106 works for any disease. The main goal is safety, not effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre for Human Drug Research (CHDR) Phase 1 Unit
RECRUITINGLeiden, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults